E/M Coding Alert - 2004 Issue 27
Inhalation Drugs: Prepare For Drastic Cuts To Albuterol And Ipratropium Reimbursement
Subscribe or sign in to view the full article.
Article Overview
This article explains upcoming Medicare payment changes for inhalation drugs commonly administered through nebulizers, and why those changes matter to physician offices that provide these therapies in-house. It covers the broader reimbursement environment, CMS coverage direction, OIG concerns about spending, and the billing implications for practices that furnish nebulizer medications and related patient education services.
Why This Topic Matters
Practices that administer inhalation drugs in-office may face major reimbursement pressure and operational changes as Medicare policy shifts coverage toward other delivery methods. The article helps billing and coding professionals understand the policy context, the affected service area, and the possible financial impact on practices.
What You Will Learn
- How Medicare reimbursement changes are affecting inhalation drugs delivered by nebulizer
- Why policy and spending scrutiny are influencing payment levels for these drugs
- How coverage changes may affect physician office billing and drug acquisition decisions
- What kinds of nebulizer-related services are discussed in the context of Medicare payment
Who Should Read This
- Medical coders
- Billing staff
- Practice managers
- Pulmonology practices
- Physician office administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com